In this NEJM article, they report a treatment for #nCoV2019.
On day 10 this patient’s condition appears to be worsening till they give him remdesivir. Made by Gilead, not yet FDA approved.
Good case for fast-tracking this drug, and possibly others. nejm.org/doi/full/10.10…
On day 10 this patient’s condition appears to be worsening till they give him remdesivir. Made by Gilead, not yet FDA approved.
Good case for fast-tracking this drug, and possibly others. nejm.org/doi/full/10.10…
Some notes: I don’t have any stock in Gilead to my knowledge (maybe through an index fund) and no affiliation.
They have a very carefully phrased statement here where they make clear this was at the request of local US officials.
gilead.com/news-and-press…
They have a very carefully phrased statement here where they make clear this was at the request of local US officials.
gilead.com/news-and-press…
Reading between the lines:
1) FDA can be vengeful if they perceive companies to be routing around their process
2) But as ACT UP shows, they also respond to public opinion
3) So Gilead itself can’t push to fast track remdesivir. Only the public can. theatlantic.com/health/archive…
1) FDA can be vengeful if they perceive companies to be routing around their process
2) But as ACT UP shows, they also respond to public opinion
3) So Gilead itself can’t push to fast track remdesivir. Only the public can. theatlantic.com/health/archive…
